Further studies would be beneficial to address the ideal anti-VEGF agent, its dosage for ROP treatment, and the optimal follow-up regimen for infants after the use of anti-VEGF agents for ROP. The gene discussed is VEGFA; the disease is retinopathy of prematurity.